melphalan

Summary

Summary: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.

Top Publications

  1. doi Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group
    Nicole Blijlevens
    Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 26:1519-25. 2008
  2. ncbi Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
  3. doi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
  4. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
  5. doi A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
  6. doi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
  7. doi A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide
    Z Ji
    Division of Environmental Health Sciences, School of Public Health, University of California at Berkeley, Berkeley, CA 94720 7360, USA
    Leukemia 24:986-91. 2010
  8. ncbi Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
  9. doi A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results
    David H Abramson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ophthalmology 115:1398-404, 1404.e1. 2008
  10. doi Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
    Peter M Fayers
    Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
    Blood 118:1239-47. 2011

Detail Information

Publications311 found, 100 shown here

  1. doi Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group
    Nicole Blijlevens
    Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 26:1519-25. 2008
    ....
  2. ncbi Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
    ..To examine mechanisms of cellular resistance to melphalan, we compared genotypic and phenotypic profiles of acquired and de novo melphalan resistance in an isogenic human ..
  3. doi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
    Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high...
  4. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
    Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete ..
  5. doi A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
    ..After induction therapy and stem cell mobilization, patients were to receive high-dose melphalan, 200 mg/m(2), followed by maintenance with alpha-interferon (arm A) or thalidomide 50 mg daily (arm B)...
  6. doi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma...
  7. doi A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide
    Z Ji
    Division of Environmental Health Sciences, School of Public Health, University of California at Berkeley, Berkeley, CA 94720 7360, USA
    Leukemia 24:986-91. 2010
    ..with HQ for 48 h, and compared the HQ-induced alterations with those induced by two well-known leukemogens, melphalan, an alkylating agent, and etoposide, a DNA topoisomerase II inhibitor...
  8. ncbi Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
    Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients...
  9. doi A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results
    David H Abramson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ophthalmology 115:1398-404, 1404.e1. 2008
    ..to cannulate repeatedly the ophthalmic artery of young children with advanced retinoblastoma, to find a dose of melphalan that would be tolerable and tumoricidal for retinoblastoma when given intraarterially, and to study the local ..
  10. doi Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
    Peter M Fayers
    Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
    Blood 118:1239-47. 2011
    ..Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone alone (MP) and with thalidomide (MPT). The effect on overall survival (OS) varied across trials...
  11. doi Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, AOU S Giovanni Battista, Turin, Italy
    Leukemia 24:1037-42. 2010
    ..non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)...
  12. doi Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria
    Blood 113:3435-42. 2009
    We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM)...
  13. doi Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longer progression-free survival (PFS) than did the standard ..
  14. ncbi High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  15. doi Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
    Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years...
  16. ncbi Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia
    J Vela-Ojeda
    Department of Hematology, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Apartado postal 14 878, Código postal 07001, Mexico D F, Mexico
    Ann Hematol 81:362-7. 2002
    ..Four patients were treated with vincristine, melphalan, cyclophosphamide, prednisone, and adriamycin (VMCPA), 12 with vincristine, adriamycin, and dexamethasone (VAD), ..
  17. pmc High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    Sumit Madan
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Blood 119:1117-22. 2012
    High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement...
  18. ncbi Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Blood 104:3052-7. 2004
    ..study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) [MEL100]) with stem ..
  19. pmc Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, The Netherlands
    Br J Cancer 82:1000-3. 2000
    ..possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-alpha) and melphalan after isolated limb perfusion (ILP) have been presented...
  20. ncbi Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
    Stephane Vigouroux
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU Pontchaillou, Rennes, France
    Haematologica 92:627-34. 2007
    ..The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT...
  21. ncbi Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
    Victoria J Spanswick
    Cancer Research UK Drug DNA Interactions Research Group, Department of Oncology, Royal Free and University College Medical School, London, United Kingdom
    Blood 100:224-9. 2002
    b>Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT)...
  22. doi BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
    Giuseppe Visani
    Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy
    Blood 118:3419-25. 2011
    ..180 mg/m², and 200 mg/m² given on days -7 and -6) coupled with fixed doses of etoposide, cytarabine, and melphalan (BeEAM regimen) as the conditioning regimen to autologous stem cell transplantation for resistant/relapsed ..
  23. doi Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases
    Carlo Riccardo Rossi
    Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    Ann Surg Oncol 17:3000-7. 2010
    ..of the perfused patients; (2) to compare toxicity, response, and survival among patients who underwent melphalan-based perfusion with or without low-dose tumor necrosis factor (TNF); and (3) to identify factors that predict a ..
  24. doi Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    D Lebovic
    Department of Medicine, Weill Cornell School of Medicine, New York Hospital, NY, USA
    Br J Haematol 143:369-73. 2008
    ..AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10...
  25. doi Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan
    Yongzhen Hu
    Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan
    Mol Cancer Ther 8:2329-38. 2009
    ..by echinomycin, a specific HIF-1 inhibitor, or a siRNA against HIF-1alpha resulted in enhanced sensitivity to melphalan in myeloma cells...
  26. doi Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
    Meral Beksac
    Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey
    Eur J Haematol 86:16-22. 2011
    The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules...
  27. ncbi Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector
    Zhen Zhou Yang
    Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China
    Clin Lymphoma Myeloma 7:296-304. 2007
    ....
  28. ncbi Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis
    B E Plaat
    Department of Pathology, University Hospital Groningen, The Netherlands
    Clin Cancer Res 5:1650-7. 1999
    Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan (HILP-TM) with or without IFN-gamma is a promising local treatment in patients with locally advanced extremity soft tissue sarcomas (STSs), with response ..
  29. doi Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas
    Jan P Deroose
    Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    J Clin Oncol 29:4036-44. 2011
    ..or facilitate function-preserving surgery can be achieved by tumor necrosis factor α (TNF) -based and melphalan-based isolated limb perfusion (TM-ILP)...
  30. doi Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis
    Shigenobu Suzuki
    Division of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ophthalmology 118:2081-7. 2011
    ..To report the success rate, adverse events, and long-term prognosis of selective ophthalmic arterial injection (SOAI) therapy for intraocular retinoblastoma...
  31. ncbi Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model
    O Glehen
    Surgical Department, Centre Hospitalo Universitaire Lyon Sud, 69495 Pierre Benite, France
    Cancer Chemother Pharmacol 54:79-84. 2004
    ..b>Melphalan is a chemotherapeutic agent that shows increased pharmacological activity with heat...
  32. ncbi Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
    Nelson Leung
    Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:270-7. 2005
    ..High-dose melphalan followed by autologous stem cell transplantation currently has become the treatment of choice...
  33. doi Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma
    Fariba Ghassemi
    Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
    Arch Ophthalmol 130:1268-71. 2012
    ..To evaluate the efficacy and complications of intravitreal chemotherapy for viable vitreous seeding from retinoblastoma...
  34. pmc The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
    Qing Chen
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, Biostatistics Core Facility, H Lee Moffitt Cancer Center and Research Institute at University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 106:698-705. 2005
    b>Melphalan, a DNA cross-linker, is one of the most widely used and effective drugs in the treatment of multiple myeloma (MM)...
  35. pmc Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
    J H de Wilt
    Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Cancer 80:161-6. 1999
    ..Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%...
  36. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008
    ..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
  37. doi Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?
    Deidra J Osher
    Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Pathol 64:924-6. 2011
    ..The patient was subsequently treated with oral melphalan therapy and has not recurred in over 25 years...
  38. doi Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma
    Wisam J Muen
    Retinoblastoma Unit, Barts and The London NHS Trust, Royal London Hospital, United Kingdom
    Ophthalmology 119:611-6. 2012
    To report the efficacy of super-selective intra-ophthalmic artery melphalan (IAM) for the treatment of refractory retinoblastoma and any associated complications of this treatment.
  39. ncbi Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients
    Ulrike Stein
    Division of Surgery and Surgical Oncology, Charite, Humboldt University, Campus Berlin Buch, Robert Rössle Hospital and Tumor Institute, Robert Rossle Strasse 10, 13092 Berlin, Germany
    J Clin Oncol 20:3282-92. 2002
    Isolated, hyperthermic limb perfusion (ILP) with recombinant human tumor necrosis factor alpha and melphalan is a highly effective treatment for advanced soft tissue sarcoma (STS) and locoregional metastatic malignant melanoma...
  40. doi Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Eur J Haematol 85:200-8. 2010
    The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide-dexamethasone (len/dex) vs. melphalan-prednisone-lenalidomide (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma.
  41. ncbi Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
    Giovanni Palladini
    Amyloid Center Biotechnology Research Laboratories, Department of Biochemistry, University Hospital, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Blood 103:2936-8. 2004
    ..Patients ineligible for ASCT are usually treated with standard oral melphalan and prednisone, but the response rate to this regimen is unsatisfactory, and time to response is long...
  42. ncbi Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome
    M Sauer
    Department of Pediatric Hematology Oncology, Hannover Medical University, Hannover, Germany
    Bone Marrow Transplant 39:143-7. 2007
    ..In an attempt to minimize regimen-related toxicity (RRT), we have initiated a fludarabine/treosulfan/melphalan-based pilot protocol avoiding the combination of busulfan and cyclophosphamide...
  43. doi Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation
    Allen C Sherman
    Behavioral Medicine, Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Biol Blood Marrow Transplant 15:12-20. 2009
    High-dose melphalan and autologous hematopoietic stem cell transplantation (HSCT) is a standard treatment for myeloma, but very little is known about the psychosocial or quality-of-life difficulties that these patients encounter during ..
  44. doi Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients
    Stephane Cherix
    Department of Orthopaedic Surgery, University Hospital, Lausanne, Switzerland
    J Surg Oncol 98:148-55. 2008
    Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft tissue sarcomas (STS) of the extremities...
  45. doi Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen.
  46. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
    ..outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago...
  47. ncbi High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Arnaud Jaccard
    Department of Hematology, Centre Hospitalier Universitaire, Université et Centre National de la Recherche Scientifique, UMR 6101, Limoges, France
    N Engl J Med 357:1083-93. 2007
    ....
  48. doi Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma
    Danielle N Yarde
    Cancer Biology Ph D Program, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 69:9367-75. 2009
    ..We recently reported that FA/BRCA genes are overexpressed and causative for drug resistance in human melphalan-resistant multiple myeloma cell lines...
  49. ncbi Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, The Netherlands
    Haematologica 92:928-35. 2007
    ..The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM)...
  50. doi Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    J Clin Oncol 28:2259-66. 2010
    The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy ..
  51. doi Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
    Anders Waage
    Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 116:1405-12. 2010
    ..placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0...
  52. doi A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma
    Georgia M Beasley
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 115:4766-74. 2009
    Isolated limb infusion with melphalan is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximately 30% complete response (CR) rate...
  53. ncbi Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro
    M Efthimiou
    Division of Genetics, Cell and Developmental Biology, Department of Biology, University of Patras, Patras 265 00, Greece
    Mutat Res 617:125-37. 2007
    b>Melphalan (MEL), chlorambucil (CAB) and p-N,N-bis(2-chloroethyl)aminophenylacetic acid (PHE) are nitrogen mustard analogues, which are clinically used as chemotherapeutic agents. They also exert carcinogenic activity...
  54. ncbi High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    J Anthony Child
    Academic Unit of Haematology and Oncology, Cancer Research United Kingdom Clinical Centre, University of Leeds, Leeds, United Kingdom
    N Engl J Med 348:1875-83. 2003
    ..In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited...
  55. ncbi p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan
    J Muret
    Department of AnesthesiaInstitut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Oncol 19:793-800. 2008
    Recombinant tumor necrosis factor-alpha (TNF-alpha) combined to melphalan is clinically administered through isolated limb perfusion (ILP) for regionally advanced soft tissue sarcomas of the limbs...
  56. ncbi Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards
    Shawn Balcome
    Department of Medicinal Chemistry, University of Minnesota Cancer Center, Room 760E, Box 806 Mayo, 420 Delaware Street Southeast, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 17:950-62. 2004
    ..The presence of cross-linked adenine-adenine lesions may explain the enhanced cytotoxicity and mutagenicity of NMs in cells deficient in N3-alkyladenine glycosylase...
  57. doi Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
    Pierre Wijermans
    Haga Hospital, Leyweg 275, The Hague, The Netherlands
    J Clin Oncol 28:3160-6. 2010
    For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)...
  58. ncbi Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020
    Wendy R Cornett
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 24:4196-201. 2006
    ..prospective multi-institutional trial whether the addition of tumor necrosis factor alpha (TNF-alpha) to a melphalan-based hyperthermic isolated limb perfusion (HILP) treatment would improve the complete response rate for locally ..
  59. doi CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
    S G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:1699-703. 2010
    The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk ..
  60. ncbi Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells
    Krzysztof Bielawski
    Department of Medicinal Chemistry and Drug Technology, Medical University of Białystok, Kilinskiego 1, 15 089 Białystok, Poland
    Biochem Pharmacol 72:320-31. 2006
    A novel amidine analogue of melphalan (AB4) was compared to its parent drug, melphalan in respect to cytotoxicity, DNA and collagen biosynthesis in MDA-MB-231 and MCF-7 human breast cancer cells...
  61. ncbi Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan
    Lorenzo Mortara
    Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy
    Eur J Immunol 37:3381-92. 2007
    ..targeted to tumor vasculature by the anti-ED-B fibronectin domain antibody L19(scFv) and combined with melphalan, induces a therapeutic immune response...
  62. doi High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    We developed a new high-dose combination of infusional gemcitabine with busulfan and melphalan for lymphoid tumors...
  63. doi Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma
    Sheelu Varghese
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 17:1870-7. 2010
    ..In this study, we characterized the early molecular changes that occur in tumors immediately after vascular isolation perfusion with melphalan with hyperthermia in patients with hepatic metastases from ocular melanoma.
  64. ncbi Acute left ventricular failure following melphalan and fludarabine conditioning
    D S Ritchie
    Bone Marrow Transplant Service, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
    Bone Marrow Transplant 28:101-3. 2001
    Cardiotoxicity has rarely been reported as a complication of melphalan or fludarabine administration as single agents...
  65. ncbi Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma
    Roberto Rodriguez
    Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91001, USA
    Biol Blood Marrow Transplant 12:1326-34. 2006
    ..with conventional myeloablative regimens (CMRs) (n = 48) and an RIR (n = 40) of fludarabine 125 mg/m(2) and melphalan 140 mg/m(2)...
  66. doi Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan
    Theodore Lialiaris
    Department of Genetics, Medical School, Demokritus University of Thrace, Alexandroupolis 68100, Greece
    Mutagenesis 23:347-54. 2008
    ..The anti-neoplastic agent melphalan (MEL), which encompasses a number of side effects, is a strong alkylating agent and a potent inducer of sister ..
  67. doi Separation and identification of trinucleotide-melphalan adducts from enzymatically digested DNA using HPLC-ESI-MS
    Dalia Mohamed
    Department of Chemistry, Laboratory of Applied Analytical and Environmental Chemistry, Humboldt Universitaet zu Berlin, Brook Taylor Str 2, 12489, Berlin, Germany
    Anal Bioanal Chem 392:805-17. 2008
    b>Melphalan is a bifunctional alkylating agent that covalently binds to the nucleophilic sites present in DNA. In this study we investigated oligonucleotides prepared enzymatically from DNA modified with melphalan...
  68. pmc Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb
    J M Klaase
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam
    Br J Cancer 70:151-3. 1994
    ..melanoma of the lower limb a total of 35 biopsies were taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and muscle tissue...
  69. ncbi Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma
    Massimo Offidani
    Clinic of Haematology, Polytechnic University of Marches, Ancona, Italy
    Hematol J 5:312-7. 2004
    ..The aim of this study was to compare the toxicity and efficacy of thalidomide alone and in combination with oral melphalan. Patients with advanced MM received 100 mg/day oral thalidomide escalated weekly up to 600 mg/day (n=23; T group)..
  70. ncbi Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 77:410-5. 2006
    We undertook a comparative study of Pegfilgrastim vs. Filgrastim after high-dose melphalan and autologous peripheral blood stem cell transplantation (APBSCT) in multiple myeloma (MM) patients...
  71. ncbi Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities
    Dirk J G Grünhagen
    Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Recent Results Cancer Res 179:257-70. 2009
    ....
  72. doi Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Ann Hematol 90:89-94. 2011
    ..engraftment, hospital stay, and supportive measures in patients with multiple myeloma after conditioning with Melphalan 200 (Mel200) followed by APBSCT...
  73. ncbi A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity
    Mary S Brady
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:1123-9. 2006
    ..Reports from Australia of efficacy similar to that of isolated limb perfusion prompted us to conduct a phase II trial to evaluate the efficacy and safety of ILI...
  74. pmc Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation
    Christa E Nath
    Department of Biochemistry and Oncology, The Children s Hospital at Westmead, NSW, Australia
    Br J Clin Pharmacol 59:314-24. 2005
    To analyse the pharmacokinetics of melphalan in 52 children (0...
  75. ncbi The nitrogen mustard melphalan activates mitogen-activated phosphorylated kinases (MAPK), nuclear factor-kappaB and inflammatory response in lung epithelial cells
    Camilla Osterlund
    Division of NBC Defence, Swedish Defence Research Agency, Umea, Sweden
    J Appl Toxicol 25:328-37. 2005
    ..agent, we exposed human bronchial (BEAS-2B) and alveolar (A549) cells to the nitrogen mustard derivative melphalan. The BEAS-2B cells were highly sensitive to melphalan, as shown by a reduced viability after a 10-min incubation ..
  76. ncbi Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy
    Katja M J Thijssens
    Department of Surgical Oncology, University Medical Center Groningen, P O Box 30 001, Groningen, RB, 9700, The Netherlands
    Ann Surg Oncol 13:518-24. 2006
    The aim was to investigate the value of adjuvant radiotherapy for locally advanced soft tissue sarcoma after hyperthermic isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan followed by limb-saving surgery.
  77. ncbi Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan
    Yasukazu Kawai
    First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Matsuoka, Japan
    Eur J Haematol 72:448-50. 2004
    ..High-dose melphalan with autologous stem cell transplantation has shown the ability to induce complete hematological response (HR) ..
  78. ncbi Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
    Giovanni Palladini
    Blood 110:787-8. 2007
  79. ncbi Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:1025-31. 2004
    ..The patients comprised two groups: those receiving standard high-dose melphalan and those receiving intermediate-dose melphalan...
  80. pmc Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients
    Christa E Nath
    Department of Biochemistry, The Children s Hospital at Westmead, NSW, Australia
    Br J Clin Pharmacol 64:151-64. 2007
    To develop a population pharmacokinetic model for melphalan in children with malignant diseases and to evaluate limited sampling strategies for melphalan.
  81. ncbi Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan
    Annett Kühne
    Department of Clinical Pharmacology, Georg August University Gottingen, Gottingen, Germany
    Pharmacogenet Genomics 17:505-17. 2007
    b>Melphalan is widely used in the treatment of multiple myeloma. Pharmacokinetics of this alkylating drug shows high inter-individual variability...
  82. ncbi Necrobiotic xanthogranuloma-rapid progression under treatment with melphalan
    Mirjana Ziemer
    Department of Dermatology, Friedrich Schiller University of Jena, Erfurter Strasse 35, 07743 Jena, Germany
    Eur J Dermatol 15:363-5. 2005
    ..We treated this extraordinary widespread condition with melphalan and prednisolone...
  83. ncbi Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion
    Dimitri A Breems
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Haematol 72:181-5. 2004
    ..One of the patients was treated with high dose melphalan chemotherapy and autologous stem cell reinfusion, resulting in a normalization of the liver enzyme tests and the ..
  84. ncbi Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA
    Br J Haematol 138:467-78. 2007
    ..To evaluate this, we examined the antimyeloma effects of ATO alone and in combination with bortezomib, melphalan and ascorbic acid (AA) both in vitro and in vivo using a severe combined immunodeficient (SCID)-hu murine ..
  85. doi Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
    Michel Delforge
    Myeloma Study Group, Belgian Hematological Society, Belgium
    Eur J Haematol 86:372-84. 2011
    ..This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs...
  86. doi Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences
    Florian Grabellus
    Institute of Pathology and Neuropathology, University Hospital Essen and Sarcoma Center at the West German Cancer Center, University of Duisburg Essen, 45122 Essen, Germany
    Ann Surg Oncol 16:676-86. 2009
    ..Isolated limb perfusion (TM-ILP) is an effective limb-sparing treatment for primarily nonresectable soft tissue sarcomas (STS). Surgical margins of STS after ILP were yet not systematically studied...
  87. ncbi In vitro evidence for homologous recombinational repair in resistance to melphalan
    Z M Wang
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, PQ, Canada
    J Natl Cancer Inst 93:1473-8. 2001
    ..cross-links is thought to be important in the cytotoxicity of nitrogen mustard alkylating agents, such as melphalan, which have antitumor activity...
  88. pmc Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?
    N McMahon
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Ann Surg Oncol 16:953-61. 2009
    This study aims to determine what effect correcting melphalan dosing for ideal body weight (IBW) has on toxicity and response in isolated limb infusion (ILI) in patients with advanced extremity melanoma.
  89. ncbi Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy
    M S Roberts
    Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia
    Melanoma Res 11:423-31. 2001
    ..b>Melphalan is the preferred cytotoxic agent for the treatment of melanoma by ILP or ILI...
  90. doi Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine
    Volodymyr Shnitsar
    Abteilung Vegetative Physiologie und Pathophysiologie, Georg August Universitat, Gottingen, Germany
    Cancer Res 69:1494-501. 2009
    ..into hOCT3 stably transfected Chinese hamster ovary (CHO) cells was inhibited by irinotecan, vincristine, and melphalan. The K(i) values [determined from Dixon plots] for irinotecan, vincristine, and melphalan were 1.72 +/- 0...
  91. doi Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients
    Hidde M Kroon
    Sydney Melanoma Unit and Melanoma Institute Australia, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia
    Ann Surg Oncol 16:1184-92. 2009
    ..Previously we have shown that more significant limb toxicity is not associated with a higher response rate or improved patient outcome. In this study we sought to determine factors predicting toxicity following ILI...
  92. doi Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma
    Hidde M Kroon
    Sydney Melanoma Unit, Sydney Cancer Center, Royal Prince Alfred Hospital, Sydney, Australia
    Cancer 115:1932-40. 2009
    ..Recurrent or progressive disease after an ILI, however, presents a challenge for further treatment. The value of repeat ILI in this situation has not been well documented...
  93. doi Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 15:610-7. 2009
    ..We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D...
  94. ncbi Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
    G Vassal
    Department of Paediatric Oncology, Institut Gustave-Roussy, Villejuif, France
    Bone Marrow Transplant 27:471-7. 2001
    ..of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single-agent melphalan administered over two consecutive courses (C1 and C2) in children...
  95. doi Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient
    Sylvie Bonvalot
    Department of Surgery, Institut Gustave Roussy, Villejuif Cedex, France
    Ann Surg Oncol 16:3350-7. 2009
    ..The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-alpha...
  96. doi Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
    Richard A Campbell
    Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
    Eur J Haematol 84:201-11. 2010
    ..Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model...
  97. doi Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma
    Hassan A Aziz
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Retina 30:S63-5. 2010
    ..The purpose of this study was to report a case of a 7-year-old girl with unilateral, multifocal Reese Ellsworth Stage Vb retinoblastoma who was successfully treated using intraarterial chemotherapy infusion as the primary therapy...
  98. ncbi High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma
    M Carli
    Department of Pediatrics, Oncology Hematology Division, University of Padova, Padova, Italy
    J Clin Oncol 17:2796-803. 1999
    The European Collaborative MMT4-91 trial was conducted as a prospective nonrandomized study to evaluate the potential benefit of high-dose melphalan as consolidation of first complete remission in children with stage IV rhabdomyosarcoma.
  99. ncbi Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery
    A L Vahrmeijer
    Department of Surgery, Leiden University Medical Center, The Netherlands
    Cancer Chemother Pharmacol 44:111-6. 1999
    ..bearing intrahepatically implanted tumors of the CC531 colorectal cancer cell line on the antitumor activity of melphalan (L-PAM)...
  100. doi Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 116:4777-82. 2010
    ..dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex), and assess the efficacy and tolerability of this therapy for patients with de novo AL ..
  101. ncbi Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Br J Haematol 117:886-9. 2002
    ..with AL amyloidosis with clinically significant cardiac involvement is 5 months when treated with cyclic melphalan and prednisone...

Research Grants72

  1. Inhibition of glutathione reductase and ovarian cancer drug resistance reversal
    Xiangming Guan; Fiscal Year: 2006
    ..first and rate-determining step in GSH biosynthesis significantly increased the sensitivity of the cell line to melphalan, a chemotherapeutic agent...
  2. Glutathione reductase and tumor sensitivity to radiation
    Xiangming Guan; Fiscal Year: 2003
    ..of GR did reduce intracellular GSH and the reduction of GSH led to an increase in the sensitivity of OVCAR-3 to melphalan, a chemotherapeutic agent...
  3. PEDIATRIC ONCOLOGY GROUP
    Stephen Lauer; Fiscal Year: 2002
    ..relapsed AML with idarubicin and chlordeoxyadenosine, treatment of relapsed solid tumors with high-dose busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-..
  4. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    CHARLES PATRICK REYNOLDS; Fiscal Year: 2010
    ..the degree of cross-resistance in a panel of 25 neuroblastoma cell lines of cyclophosphamide, carboplatin, melphalan (L-PAM) alone and in combination with topoisomerase inhibitors or BSO under standard culture conditions (20% O2) ..
  5. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..The conditioning regimen will consist of fludarabine-melphalan-campath...
  6. ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA
    Charles Reynolds; Fiscal Year: 2001
    ..depletion of glutathione (GSH) by buthionine sulfoximine (BSO) has a cytotoxic synergy with the alkylator melphalan (L-PAM) that is antagonized by hypoxia and 2) that retinoids improve survival in high-risk neuroblastoma but may ..
  7. Detoxification of Electrophilic Chemical Threat Agents by Nucleophilic Scavengers
    MICHAEL MACLEOD; Fiscal Year: 2007
    ..Both of these have been shown to completely detoxify the carcinogen BPDE. DTP has also been shown to detoxify melphalan, a nitrogen mustard, and in preliminary studies we have demonstrated facile reaction of DTP with a sulfur ..
  8. GLUTATHIONE MODULATION OF ALKYLAYTORS IN MEDULLOBLASTOMA
    Henry Friedman; Fiscal Year: 1993
    ..have documented the activity of a series of bifunctional alkylating agents including cyclophosphamide and melphalan in the treatment of a panel of medulloblastoma cell lines and transplantable xenografts...
  9. AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
    ROBERTA COLMAN; Fiscal Year: 1999
    ..g., the 1-1 isozyme confers the greatest cellular resistance to the anti-cancer drugs, chlorambucil and melphalan, while the 3-3 isozyme confers the most increase in resistance to cisplatin...
  10. Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
    Alan Sartorelli; Fiscal Year: 2009
    ..brain barrier, is active both orally and parenterally, is not cross-resistant with cyclophosphamide, BCNU, or melphalan, and a by-product of its activation, methyl isocyanate, has synergistic cytotoxic activity with the generated ..
  11. Development of Anticancer 1,2-Bis(sulfonyl)hydrazines
    Alan Sartorelli; Fiscal Year: 2007
    ..brain barrier, is active both orally and parenterally, is not cross-resistant with cyclophosphamide, BCNU, or melphalan, and a by-product of its activation, methyl isocyanate, has synergistic cytotoxic activity with the generated ..